Immunoconjugates for treating bladder cancer
A PD1-IL2v immunoconjugate targeting PD-1+ T cells enhances IL-2 signaling and immune response in bladder cancer, offering a promising treatment for BCG-unresponsive NMIBC by increasing CD8 T cell infiltration and survival benefits, comparable to IL-15 receptor agonists.
WO2026132565A1PCT designated stage Publication Date: 2026-06-25F HOFFMANN LA ROCHE & CO AG +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- F HOFFMANN LA ROCHE & CO AG
- Filing Date
- 2025-12-19
- Publication Date
- 2026-06-25
Smart Images
Figure IMGF000011_0001 
Figure IMGF000016_0001 
Figure IMGF000021_0001
Abstract
The application relates to immunoconjugates for use in a method of treating bladder cancer in a human patient, wherein the method comprises administering the immunoconjugate to the patient, wherein the immunoconjugate comprises: (i) an antibody that binds to PD-1; and (ii) a mutant IL-2 polypeptide comprising the amino acid substitutions F42A, Y45A and L72G. The immunoconjugates are capable of binding in cis to PD-1 and stimulating IL-2 signalling on the same cell, providing selective IL-2 receptor signalling on PD-1 positive T cells relative to the PD-1 negative T cells. The application also relates to the use of the immunoconjugates in combination with immunotherapeutic agent, which is bacterial strain or an oncolytic virus, such as the BCG vaccine.
Need to check novelty before this filing date? Find Prior Art